Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540341 | 0.78 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6MAPT | |
| SCHEMBL5871368 | 0.77 | PRCP (0.42) | CYP2D6MAPTMEN1KMT2A | |
| SCHEMBL2345152 | 0.76 | ESR2 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6MAPT | |
| SCHEMBL8363609 | 0.73 | MAPT (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6MAPT | |
| SCHEMBL28612780 | 0.73 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3CYP2D6MAPT | |
| SCHEMBL29641649 | 0.73 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3CYP2D6MAPT | |
| SCHEMBL2631582 | 0.71 | CA1 (0.49) | MAPTMEN1KMT2APOLBACHE | |
| SCHEMBL21707867 | 0.71 | CA1 (0.49) | MAPTMEN1KMT2APOLBACHE | |
| SCHEMBL28639874 | 0.70 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3CYP2D6MAPT | |
| SCHEMBL28639875 | 0.70 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| WO-2011103460-A1 | FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103460-A1 | FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | SLC6A2 60/4885SLC6A4 8/4885SLC6A3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.